Bibliotecas PUC-SP - Busca Integrada

Arsenic and all-<i>trans</i> retinoic acid for acute promyelocytic leukemia: yes, it really is as good as it seems

Yazar: Mark Levis
Yayımlandı Haematologica (2021-05-01)

The current therapeutic landscape of FLT3 inhibitors

Yazar: Mark Levis
Yayımlandı Blood Advances (2017-10-01)

Inhibition of c-Kit by tyrosine kinase inhibitors

Yazar: Allison Galanis, Mark Levis
Yayımlandı Haematologica (2015-03-01)

Potential targeting of <i>FLT3</i> acute myeloid leukemia

Yazar: Alexander J. Ambinder, Mark Levis
Yayımlandı Haematologica (2020-07-01)

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation

Yazar: Ruiqi Zhu, Li Li, Bao Nguyen, Jaesung Seo, Min Wu, Tessa Seale, Mark Levis, Amy Duffield, Yu Hu, Donald Small
Yayımlandı Signal Transduction and Targeted Therapy (2021-05-01)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia

Yazar: Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Benjamin Powell, Chao Zhang, Yan Ma, Maiko Narahara, Hiroyuki Sumi, Daniela Hernandez, Trivikram Rajkhowa, Gideon Bollag, Mark Levis
Yayımlandı Haematologica (2021-01-01)

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

Yazar: Vinod A. Pullarkat, Mark Levis, James McCloskey, Gabriel N. Mannis, Stephen A. Strickland, Amir T. Fathi, Tara L. Lin, Vijaya R. Bhatt, Thuva Vanniyasingam, Divya Chakravarthy, Yana Lutska, Stefan Faderl, Ronald S. Cheung, Harry P. Erba
Yayımlandı Blood Neoplasia (2025-11-01)

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

Yazar: Paul Milne, Charlotte Wilhelm-Benartzi, Michael R. Grunwald, Venetia Bigley, Richard Dillon, Sylvie D. Freeman, Kathleen Gallagher, Amy Publicover, Sarah Pagan, Helen Marr, Gail L. Jones, Anne M. Dickinson, Angela Grech, Alan K. Burnett, Nigel H. Russell, Mark Levis, Steven Knapper, Matthew Collin
Yayımlandı Blood Advances (2019-10-01)

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia

Yazar: Keith W. Pratz, Jason Kaplan, Moshe Levy, Dale Bixby, Patrick W. Burke, Harry Erba, Trisha M. Wise-Draper, Gail J. Roboz, Nikolaos Papadantonakis, Trivikram Rajkhowa, Daniela Hernandez, Iwona Dobler, Richard C. Gregory, Cheryl Li, Shining Wang, Kate Stumpo, Karuppiah Kannan, Harry Miao, Mark Levis
Yayımlandı Haematologica (2022-10-01)

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome

Yazar: Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, Veronica Guerra, Gautam Borthakur, Yesid Alvarado, Courtney D DiNardo, Tapan Kadia, Guillermo Garcia-Manero, Maro Ohanian, Naval Daver, Marina Konopleva, Naveen Pemmaraju, Alessandra Ferrajoli, Michael Andreeff, Nitin Jain, Zeev Estrov, Elias J Jabbour, William G Wierda, Sherry Pierce, Maria Rhona Pinsoy, Lianchun Xiao, Farhad Ravandi, Jorge E Cortes
Yayımlandı Haematologica (2021-04-01)

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Yazar: Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, Friedrich Stölzel, Cristina Gil, H. Christian Reinhardt, Eliana Aguiar, Kerstin Schäfer-Eckart, Juan Miguel Bergua Burgues, Björn Steffen, Teresa Bernal, Stefan W. Krause, Rosalía Riaza, Christoph Schliemann, Jose Cervera, Martin Kaufmann, Laura Torres-Miñana, Mathias Hänel, Evelyn Acuña-Cruz, Edgar Jost, Jesus Lorenzo Algarra, Martina Crysandt, Lars Fransecky, Javier Cornago-Navascues, Sabrina Kraus, Joaquin Martinez-Lopez, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Ruth Seggewiß-Bernhardt, Sebastian Scholl, Stefan A. Klein, Christoph Schmid, Markus Schaich, Martin Schmidt-Hieber, Sven Zukunft, Anthony D. Ho, Uwe Platzbecker, Claudia D. Baldus, Carsten Müller-Tidow, Christian Thiede, Martin Bornhäuser, Hubert Serve, Mark Levis, Pau Montesinos, Christoph Röllig, Richard F. Schlenk
Yayımlandı Haematologica (2022-06-01)